Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.15)
# 3,453
Out of 4,778 analysts
85
Total ratings
36.14%
Success rate
-22.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $4.73 | - | 1 | Mar 14, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $170 → $200 | $161.11 | +24.14% | 17 | Feb 25, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $8.13 | - | 5 | Feb 7, 2025 | |
| ACRV Acrivon Therapeutics | Initiates: Overweight | n/a | $5.40 | - | 1 | Jan 31, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.72 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $18.03 | - | 2 | Jan 13, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $7.13 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $0.88 | - | 7 | Nov 19, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.40 | - | 4 | Oct 7, 2024 | |
| YMAB Y-mAbs Therapeutics | Reiterates: Overweight | $20 | $5.10 | +292.16% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.84 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.49 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.58 | - | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.93 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.22 | +145.90% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $4.15 | +5,201.20% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.90 | +453.65% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,140 | $3.29 | +34,550.46% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.44 | +2,538.89% | 1 | Aug 12, 2022 |
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.73
Upside: -
Ascendis Pharma
Feb 25, 2025
Maintains: Overweight
Price Target: $170 → $200
Current: $161.11
Upside: +24.14%
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.13
Upside: -
Acrivon Therapeutics
Jan 31, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.40
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.72
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.03
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.13
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.88
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.40
Upside: -
Y-mAbs Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $5.10
Upside: +292.16%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.84
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.49
Upside: -
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.58
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.93
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.22
Upside: +145.90%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $4.15
Upside: +5,201.20%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.90
Upside: +453.65%
Sep 7, 2023
Reiterates: Overweight
Price Target: $1,140
Current: $3.29
Upside: +34,550.46%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.44
Upside: +2,538.89%